The role of patient advocacy organisations in neuromuscular disease R&D – The case of the Dutch neuromuscular disease association VSN
Authors:
- Wouter BoonWBWouter Boon
- Ria BroekgaardenRBRia Broekgaarden
- 1 February 2010
- journal article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 20 (2) , 148-151
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The role of users in innovation in the pharmaceutical industryDrug Discovery Today, 2008
- The experiential knowledge of patients: a new resource for biomedical research?Social Science & Medicine, 2005
- Is pharmaceutical R&D just a game of chance or can strategy make a difference?Drug Discovery Today, 2004
- The struggle against neuromuscular diseases in France and the emergence of the “partnership model” of patient organisationSocial Science & Medicine, 2003
- The Third Wave of Science StudiesSocial Studies of Science, 2002
- Ten years of ENMC – from a patients’ initiative to a successful European research institution: the story of the European Neuromuscular CentreNeuromuscular Disorders, 2000
- Activism, Drug Regulation, and the Politics of Therapeutic Evaluation in the AIDS Era: A Case Study of ddC and the `Surrogate Markers' DebateSocial Studies of Science, 1997
- The European Neuromuscular Centre (ENMC): importance of collaborative researchNeuromuscular Disorders, 1997